Trump’s ‘Warp Speed’ Initiative Could Fund 3 to 5 Large-Scale COVID Vaccine Trials
Executive Summary
FDA’s Peter Marks and Janet Woodcock will be on the bridge for Operation Warp Speed; Moncef Slaoui says early clinical data on one vaccine candidate makes him confident that a few hundred million doses of a vaccine can be available by the end of the year.
You may also be interested in...
AstraZeneca, Janssen, Novavax Likely To Be Next ‘Warp Speed’ Vaccines In Phase III
While AstraZeneca’s adenovirus candidate is expected to use Operation Warp Speed’s platform, its start date remains cloaked; the Janssen and Novavax candidates are expected to enter Phase III in September and October, respectively.
Regeneron COVID-19 Therapeutic, Novavax Vaccine Get BARDA Funding To Boost Manufacturing
US government to own doses of Regeneron's investigational cocktail antibody REGN-COV2 manufactured under a $450m contract and 100 million doses of Novavax's investigational vaccine under a $1.6bn agreement.
Hope Is Not A Plan: Manufacturing COVID-19 Therapeutics
Duke-Margolis discussion emphasizes biopharma sector must quickly collaborate on manufacturing coronavirus therapeutics likely to be authorized or approved in coming months.